Insider Purchases: Inside the Buy
Tag: Funanc1alHumor
Arrow Electronics: A Straight Arrow, But the CEO Sees a Bullet
Arrow Electronics CEO Sean Kerins just bought nearly $1M of ARW stock. Is this undervalued tech distributor about to rebound, or just cruising under the radar? We take a shot at the bullseye—with puns and charts.
MSCI Keeps Winning — and the CEO Keeps Buying In
MSCI delivers world-class data tools for investors—and its CEO just bought in big. With soaring revenue, recurring subscriptions, and loyal institutions, is this still a buy? Or has the stock outpaced its fundamentals?
UPS: Shipping Value in an Expensive Market — Or Delivering a Value Trap?
UPS insiders are shipping signals of confidence 📬 with big stock purchases—even as growth slows and margins come under pressure. Should you get in on this box of value or beware what’s inside?
Does Align Technology’s Recovery Plan Have Teeth? The CEO Thinks So.
Align Technology insiders are smiling—because they’re buying. With a CEO purchase nearing $1M and Wall Street holding more shares than exist, ALGN may be regaining its shine. But should you sink your teeth into it now?
EPD: Enterprise Products Partners Is Boring—But It Pays to Be Boring
Enterprise Products Partners (EPD) might not make headlines, but it makes money. With insiders buying big, a solid 7% dividend, and decades of steady growth, this is one midstream stock that flows cash — not drama.
Insiders Bought "MicroStrategy" Shares at $90. You’re Paying $394.66. Should You?
MSTR insiders are buying, but not the stock you think. They bought STRC at $90 — while MSTR trades near $400. What gives? We break down the numbers, the Bitcoin twist, and what might be worth nibbling on.
Progress Software CEO Buys In — Maybe It’s More Than Just... Progress?
Progress Software's CEO and a director are buying shares, signaling confidence as the company posts strong earnings and raises guidance. With institutional investors owning over 121% of the float, is this under-the-radar compounder set for a rerating?
New CEO Buys In at Dave & Buster’s ($PLAY). Who Doesn’t Like a Little PLAY in Their Portfolio — or Life?
New CEO Tarun Lal takes the reins—and a big slice of $PLAY stock. With insiders buying, institutions overloaded, and sales trends improving, could this be the next comeback classic of the “entertainment” era?
Can Elevance Reach Higher Elevations? The CEO Thinks So
📉 After falling nearly 50% from its highs, Elevance Health just got a $2.4M vote of confidence from its CEO. Is this the cure—or just another symptom? 🏥 Dive into the numbers, the risks, and the potential rewards. And yes, there will be icons. 📊💊📈
Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥